MarketInOut Stock Screener Log In | Sign Up

Ondine Biomedical Inc

LSE • Healthcare • Biotechnology • Quote as of 10/27/2026 16:35
Ondine Biomedical Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeLSE
Market Capitalization62.88 mln
Float335 mln
Earnings Date05/20/2027

Piotroski F-Score

3 / 9
Below average

Beneish M-Score

-4.42
Highly reliable

1-Year Forecast

29.00
Transformational upside

Relative Strength

5 / 100
Severely lagging

Pre-Tax Margin

-1,151%
Severely loss-making

ROE

-9,268
Deeply negative

Business Description

Founded in Vancouver in 1996, Ondine Biomedical develops treatments designed to kill harmful bacteria and other pathogens that patients can pick up during hospital stays. The company's flagship offering, Steriwave, works quickly to remove these dangerous microorganisms, helping to make medical environments safer. Ondine also has a range of treatments in development targeting conditions such as wound infections, sinus problems, and infections linked to breathing tubes, catheters, and intravenous lines.

Key Fundamentals

EPS-3.00
ROE-9,268
RPS0.00
ROIC-963
ROA-311
Interest Cover-1,191
EBITDA, mln-17.53
EV / EBITDA-2.48
EV / EBIT-2.44
Revenue, mln1.55
EV / Revenue28.04

Quote Details

Last 9.50
Change -0.25 (-2.56%)
Open 9.75
Volume 815,764
Turnover 7,749,758
Average Volume 610,065

Financial Ratios

Pre-Tax Profit Margin-1,151
Current Ratio0.65
Price / Sales32.50

Financial Strength

Altman Z-Score-31.92
Piotroski F-Score 3 / 9
Beneish M-Score-4.42
1-Year Target Price29.00

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -5% 9 / 100   
1 Month -17.39% 4 / 100   
2 Months -36.67% 3 / 100   
6 Months -13.71% 14 / 100   
1 Year -30.91% 9 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Blog